Medistim ASA (0OCD) Q2 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning everyone and welcome to the second quarter and first half 2025 financial results presentations from Medistim. My name is Kari Krogstad and as usual I'm joined by my good colleague CFO Thomas Jakobsen and together we will take you through the results. And just before we dive into the highlights, we like to start by reminding everyone of our track record. This is a great reminder of our goal and ambition, which has been and still is to deliver profitable and growth consistently over time. So we can see quarter variations, but our track record shows that we have succeeded to deliver on this promise over the years. But now let's look at the second quarter and the second quarter highlights. So I'm very happy and proud to be able to present the second best quarter, both for sales and EBIT, and it's actually only beaten by the first quarter this year. So we're seeing revenue performance at 169.1 million NOX, which is 16.7% growth over the same quarter last year. And as this slide shows, there is only a slight currency effect here. So if we look at the currency neutral sales development, the total sales is up 15.7%. And as always, we are extremely satisfied to see that it's our own products that are providing and really delivering this great growth. So own product sales, currency neutral, is up 18.2%. Looking closer at the regions, Americas, as we can see, very, very strong performance this quarter. 32.9% currency neutral growth. And Americans are actually accounting for more than 80% of the total nominal revenue increase for this quarter. So that speaks to the importance of this region. Asia Pacific also providing great growth this quarter, up 22.9%. And here is definitely China, which is back on track and really driving this growth. But interestingly, we're al...